Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
13 stories
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
Cohort 2 dosing wraps in the BEST1 program, the LCA5 Phase 3 trial is fully enrolled, and an RDH12 IND clearance adds a third clinical-stage gene therapy as cash runway extends into 2029.
SEC filing
The deal brings four commercial drugs into CorMedix's hospital business for $145 million cash plus stock, with Heron staying public to pursue new ventures.
SEC filing (3)
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
Arbutus Biopharma said it can resume U.S. clinical development of AB-101, its oral PD-L1 inhibitor for chronic hepatitis B, after the FDA removed the hold.
SEC filing, Drugs@FDA (2)
The deal, announced October 8, 2026, values Pacira's equity at $1.65 billion and would add the non-opioid pain drugs EXPAREL and ZILRETTA to Viatris's portfolio.
SEC filing (2)
Harrow paid $30 million up front for the dry eye nasal spray, with up to $70 million more tied to future sales milestones.
SEC filing